Inotiv, Inc.

Inotiv, Inc. operates as a pharmaceutical development company, which engages in the provision of drug discovery, development services, and analytical instruments. The firm operates through the following business segments: Research Services and Research Products. The Research Services segment provides screening and pharmacological testing, preclinical safety testing, formulation development, regulatory compliance, and quality control testing. The Research Products segment designs, develops, manufactures, and markets vivo sampling systems and accessories, physiology monitoring tools, liquid chromatography, and electrochemistry instruments platforms. The company was founded by Peter T. Kissinger in 1974 and is headquartered in West Lafayette, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Inotiv, Inc. reports robust Q4 earnings, eyes sales growth opportunities

Inotiv, Inc. delivered strong financial performance in Q4 2022, with a focus on revenue growth and margin enhancement. Despite challenges in the NHP business and operational disruptions, the company remains optimistic about future prospects and anticipates significant sales growth from recent price increases.

Inotiv reports robust revenue growth in Q1 2023 earnings call

Inotiv Inc. demonstrated strong revenue growth in Q1 2023, despite facing challenges with negative adjusted EBITDA. The company's focus on cost reductions, pricing increases, and operational enhancements presents opportunities for future growth. Inotiv remains optimistic about its future prospects, having made tough decisions to improve its performance.

Inotiv reports revenue growth and EBITDA improvement, faces guidance challenges

Inotiv's Q2 showed revenue growth and EBITDA improvement, driven by DSA and RMS segments. Despite challenges with increased expenses and guidance adjustments, the company remains focused on margin improvements, supplier vetting, and investor engagement.

Inotiv reports robust Q3 earnings amidst NHP supply challenges

Inotiv's Q3 2023 earnings call highlighted strong financial performance, strategic initiatives, and challenges related to NHP supply.
The company's focus on operational optimization, cost reduction, and growth opportunities underscores a commitment to sustainable expansion.
Despite industry challenges, Inotiv remains confident in achieving long-term EBITDA margins of 18-22% and is actively addressing supply chain issues.
Proactive measures to manage NHP supply challenges and explore revenue growth opportunities position Inotiv for continued success in the CRO industry.

Inotiv reports robust fiscal 2023 performance and strategic growth outlook

Inotiv's strong fiscal performance in 2023 and strategic initiatives position the company for continued growth and operational excellence in 2024.
While challenges in the NHP market and uncertainties in certain service segments exist, Inotiv's focus on innovation and efficiency mitigates potential risks.
Opportunities for revenue growth through service expansion, cost reductions, and customer relationship enhancement underscore a positive outlook for the company.
By leveraging strengths in operational efficiency, service quality, and market positioning, Inotiv aims to solidify its position as a leading CRO provider and drive sustainable growth.

Inotiv reports strong Q1 results, eyes growth through acquisitions

Inotiv's Q1 performance reflects positive momentum with revenue growth and improved profitability. The company's strategic focus on operational efficiency, acquisitions, and expansion sets the stage for future success. Challenges lie in sustaining growth through effective cost management and operational optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Inotiv, Inc. is a pharmaceutical development company, which engages in the provision of nonclinical and analytical drug discovery and development services primarily to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to academia and government clients. It operates under the Discovery and Safety Assessment (DSA) and Research Models and Services (RMS) segments. The DSA segment focuses on drug discovery and development services. The RMS segment includes commercial production and selling research models, diets, bedding, and bioproducts. The company was founded by Peter T. Kissinger in 1974 and is headquartered in West Lafayette, IN.

WEST LAFAYETTE, Ind., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced the acquisition of the rabbit breeding and supply business of Robinson Services Inc. (“RSI”), a North Carolina-based provider of high-quality animal models.

Inotiv, Inc. Announces the Acquisition of the Rabbit Breeding and Supply Business of Robinson Services Inc. (“RSI”)

-- Expected to establish a leading global provider of full-spectrum, preclinical and clinical biotherapeutics and biomarker analysis solutions -- -- Expected to enhance scale, broaden customer base and create significant cross-selling opportunities --

Inotiv, Inc. and Synexa Life Sciences Sign Letter of Intent to Establish Center of Excellence for Biotherapeutics and Biomarkers

Inotiv, Inc. (NOTV) CEO Bob Leasure on Q4 2021 Results - Earnings Call Transcript

Inotiv (NASDAQ:NOTV) reported its Q4 earnings results on Thursday, December 16, 2021 at 04:05 PM. Here's what investors need to know about the announcement.

Inotiv: Q4 Earnings Insights

WEST LAFAYETTE, Ind., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months (“Q4 FY 2021”) and twelve months (“12M FY 2021”) ended September 30, 2021.

Inotiv, Inc. Announces Fourth Quarter and Full Year Fiscal 2021 Financial Results

Inotiv (NASDAQ:NOTV) is set to give its latest quarterly earnings report on Thursday, 2021-12-16. Here's what investors need to know before the announcement.

A Preview Of Inotiv's Earnings

WEST LAFAYETTE, Ind., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that the Company will issue its financial results press release for the fiscal 2021 fourth quarter ended September 30, 2021, on Thursday, December 16, 2021, after the close of the stock market and host a conference call the same day at 4:30 p.m. Eastern Time to discuss the results.

Inotiv, Inc. Reschedules Fourth Quarter Fiscal 2021 Financial Results and Conference Call for Thursday, December 16, 2021

WEST LAFAYETTE, Ind., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that its Research Models and Services (“RMS”) business, consisting of recently-acquired Envigo, has launched novel transgenic rodent models designed specifically for SARS-CoV-2 (COVID-19) and Coronavirus research.

Inotiv, Inc. Announces the Launch of New Genetically Engineered Rodent Models for SARS-CoV-2 (COVID-19) Research

The stock price of Inotiv Inc (NASDAQ: NOTV) increased by over 19% during intraday trading today. This is why it happened.

Inotiv Stock (NOTV): Why The Price Surged Today

-- Company To Reschedule Its Financial Results Conference Call -- -- Company To Reschedule Its Financial Results Conference Call --

Inotiv, Inc. Announces Select Preliminary Unaudited Financial Results for the Fourth Quarter and Full Year Fiscal 2021

Inotiv, Inc. (NOTV) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Bears are Losing Control Over Inotiv, Inc. (NOTV), Here's Why It's a 'Buy' Now

Inotiv (NASDAQ:NOTV) is set to give its latest quarterly earnings report on Tuesday, 2021-12-07. Here's what investors need to know before the announcement.

Inotiv Earnings Preview

WEST LAFAYETTE, Ind., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that the Company will issue its financial results press release for the fiscal 2021 fourth quarter ended September 30, 2021, on Tuesday, December 7, 2021, after the close of the stock market and host a conference call the same day at 4:30 p.m. Eastern Time to discuss the results.

Inotiv, Inc. to Report Fourth Quarter Fiscal 2021 Financial Results and Host Conference Call on Tuesday, December 7, 2021

Bluegreen Vacations 

Clearfield

Level One Bancorp Inc

Sterling Construction

We have narrowed down our search to five small business operators that have popped more than 20% in the past month. These are NOTV, STRL, LEVL, CLFD and BVH.

Top 5 High-Flying Small-Cap Stocks to Tap Wall Street Rally

WEST LAFAYETTE, Ind., Nov. 10, 2021 (GLOBE NEWSWIRE) -- November 10, 2021 -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced the opening of its newly-constructed, scientific laboratories at its St. Louis facility with operations focused on supporting clients in the areas of drug metabolism & pharmacokinetics (DMPK), cell & molecular biology, pharmacology, toxicology and histopathology.

Inotiv, Inc. Announces Opening of Newly-Constructed Laboratories at St. Louis Facility

Creates a Full-Spectrum Discovery-to-Approval Solution for Drug Developers Creates a Full-Spectrum Discovery-to-Approval Solution for Drug Developers

Inotiv, Inc. Completes Purchase of Envigo

WEST LAFAYETTE, Ind., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, today announced that, at a special meeting of shareholders (the “Special Meeting”) held today, Inotiv shareholders approved, among other matters, an increase in the Company's authorized shares and the issuance of Inotiv common shares to the stockholders and option holders of Envigo RMS Holding Corp. (“Envigo”) in connection with the acquisition of Envigo by merger of Envigo with a newly formed, wholly owned subsidiary of the Company. Approval of these matters by the Inotiv shareholders was a condition to the closing of the acquisition.

Inotiv, Inc. Shareholders Approve Acquisition of Envigo

The stock price of Inotiv Inc (NASDAQ: NOTV) increased by over 7% this week. This is why it happened.

NOTV Stock: Why It Increased This Week

WEST LAFAYETTE, Ind., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, today announced the acquisition of Plato BioPharma, Inc. (“PBI”), a Colorado-based, in vivo pharmacology research and drug discovery company specializing in cardiovascular, renal, pulmonary and hepatic therapeutic areas. Transaction consideration totaled $15.0 million, consisting of: $10.0 million in cash; 57,587 Inotiv common shares having a value of $2.0 million based on the weighted average closing price of Company shares as reported by NASDAQ for the twenty trading-day period ending on September 29, 2021; and $3.0 million in unsecured promissory notes.

Inotiv, Inc. Announces Expansion of In Vivo Pharmacology Offering with Acquisition of Plato BioPharma, Inc.

WEST LAFAYETTE, Ind., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, today announced the closing of its offering of $140,000,000 aggregate principal amount of 3.25% convertible senior notes due 2027 (the “notes”), including $15,000,000 of additional notes, in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The Company's obligations under the notes are guaranteed by BAS Evansville, Inc., a wholly owned subsidiary of the Company.

Inotiv, Inc. Announces Closing of $125 Million Convertible Senior Notes Offering and Full Exercise of Option to Purchase Additional $15 Million of Notes

NEW YORK, Sept. 27, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Inotiv, Inc. ("NOTV" or the "Company") (NOTV  )relating to its proposed merger with Envigo RMS Holding Corp. Under the terms of the agreement, NOTV shareholders are expected to own 64% of the combined company.

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Inotiv, Inc. - NOTV

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of Inotiv, Inc. (NASDAQ: NOTV) and Envigo RMS Holding Corp. is fair to Inotiv shareholders. Upon closing of the transaction, Inotiv shareholders are expected to own approximately 64% of the combined company on a fully diluted basis. Halper Sadeh encourages Inotiv shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper

Inotiv Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Inotiv, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – NOTV

WEST LAFAYETTE, Ind., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, today announced the pricing of its offering of $125,000,000 aggregate principal amount of 3.25% convertible senior notes due 2027 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering size was increased from the previously announced offering size of $110,000,000 aggregate principal amount of notes. The notes will be fully and unconditionally guaranteed, on a senior, unsecured basis, by BAS Evansville, Inc., a wholly owned subsidiary of Inotiv (the “guarantor”). The issuance and sale of the notes are scheduled to settle on September 27, 2021, subject to customary closing conditions. Inotiv also granted the initial purchaser of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $15,000,000 principal amount of notes.

Inotiv, Inc. Prices Upsized $125 Million Convertible Senior Notes Offering

WEST LAFAYETTE, Ind., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, today announced its intention to offer, subject to market and other conditions, $110,000,000 aggregate principal amount of convertible senior notes due 2027 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The notes will be fully and unconditionally guaranteed, on a senior, unsecured basis, by BAS Evansville, Inc., a wholly owned subsidiary of Inotiv (the “guarantor”). Inotiv also expects to grant the initial purchaser of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $16,500,000 principal amount of notes.

Inotiv, Inc. Announces Proposed Convertible Senior Notes Offering

Inotiv Inc (NASDAQ:NOTV), a contract research organization, has agreed to acquire Envigo RMS Holding Corp in a cash and stock transaction. Envigo is a provider of research models and services.

News for Inotiv, Inc. Stock (NOTV)